PGE2 Promotes Apoptosis Induced by Cytokine Deprivation through EP3 Receptor and Induces Bim in Mouse Mast Cells by Kovarova, Martina & Koller, Beverly H.
PGE2 Promotes Apoptosis Induced by Cytokine
Deprivation through EP3 Receptor and Induces Bim in
Mouse Mast Cells
Martina Kovarova1¤, Beverly H. Koller1,2*
1 Department of Medicine, Pulmonary Division, University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States of America, 2 Department of Genetics,
University of North Carolina, Chapel Hill, Chapel Hill, North Carolina, United States of America
Abstract
Increased mast cell numbers are observed at sites of allergic inflammation and restoration of normal mast cell numbers is
critical to the resolution of these responses. Early studies showed that cytokines protect mast cells from apoptosis,
suggesting a simple model in which diminished cytokine levels during resolution leads to cell death. The report that
prostaglandins can contribute both to recruitment and to the resolution of inflammation together with the demonstration
that mast cells express all four PGE2 receptors raises the question of whether a single PGE2 receptor mediates the ability of
PGE2 to regulate mast cell survival and apoptosis. We report here that PGE2 through the EP3 receptor promotes cell death of
mast cells initiated by cytokine withdrawal. Furthermore, the ability of PGE2 to limit reconstitution of tissues with cultured
mast cells is lost in cell lacking the EP3 receptor. Apoptosis is accompanied by higher dissipation of mitochondrial potential
(DYm), increased caspase-3 activation, chromatin condensation, and low molecular weight DNA cleavage. PGE2 augmented
cell death is dependent on an increase in intracellular calcium release, calmodulin dependent kinase II and MAPK activation.
Synergy between the EP3 pathway and the intrinsic mitochondrial apoptotic pathway results in increased Bim expression
and higher sensitivity of mast cells to cytokine deprivation. This supports a model in which PGE2 can contribute to the
resolution of inflammation in part by augmenting the removal of inflammatory cells in this case, mast cells.
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Introduction
Mast cells are long-lived tissue resident cells found throughout
the body primarily in association with blood vessels, nerves, and in
proximity to surfaces that interface the external environment.
Upon activation, mast cells release inflammatory mediators,
including histamine, proteases, prostaglandins, leukotrienes and
cytokines [1]. Mast cells have an important function in several
physiological as well as pathophysiological processes including host
defense, especially in response to parasites, allergic reaction and
inflammation. It is, therefore not surprising, that mast cell
numbers increase at sites of inflammation during the course of
the response. For example, elevated numbers of mast cells are
observed in the submucosa of the lungs of asthmatics [2,3], allergy
[4], rheumatoid arthritis [5,6], and chronic allergic dermatitis [6].
During the resolution phase of inflammation, homeostasis is
reestablished in inflamed tissues and mast cell numbers decline.
For many immune cells, survival at the site of inflammation is
enhanced by cytokines, and therefore a decrease in local levels of
these mediators, as the threat to the organism is neutralized, can
lead to apoptosis. ‘‘Cytokine withdrawal’’ has been reported to
activate an intrinsic (mitochondrial) apoptotic pathway in immune
cells resulting in compromised mitochondrial integrity [7]. The
mitochondrial integrity is guarded by Bcl-2 protein family
members including anti-apoptotic proteins Bcl-2, Bcl-XL, Mcl-1,
A1 and pro-apoptotic proteins Bax, Bak, Bim, Bid, Puma, Noxa,
Bad, Bik, Bmf and Hrk. Mitochondrial outer membrane
permeabilisation (MOMP) occurs when the balance of these
factors is markedly disturbed. MOMP results in the release of
principal killing factors such as cytochrome c and Smac/DIABLO
from mitochondria to cytoplasm, where they contribute to the
formation of apoptosome and activate aspartate-specific cysteine
proteases (caspases) including initiator caspase-9. Caspase-9 in
turn cleaves and induces the activation of downstream effector
caspases that degrade and disassemble the cell [7].
Mast cell survival is regulated primarily by Stem cell factor
(SCF), the ligand of c-kit receptor, through inactivation of the
Forkhead transcription factor FOXO3a by MEK/MAPK- and
PI3-kinase-mediated phosphorylation. Phosphorylation of
FOXO3a also leads to phosphorylation, subsequent ubiquitination
and proteasomal degradation of proapoptotic Bim and Puma.
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Upon cytokine withdrawal, phosphorylation of FOXO3a decreas-
es, followed by increase in Bim and Puma expression and
apoptosis [8].
Prostaglandin E2 (PGE2), a bioactive mediator elevated at sides
of inflammation, exerts its biological function through four distinct
membrane-bound G-coupled receptors EP1- EP4. PGE2 can
contribute to resolution of inflammation by stimulating the
expression of lipid mediators involved in the regulation of
phagocytic clearance of apoptotic cells and by suppressing of the
initial inflammatory response [9]. Here we examine the ability of
PGE2 to contribute to the resolution of inflammation, specifically,
the removal of mast cells from inflammatory sites.
Material and Methods
Chemicals
LY294002, PD98059, PGE2, KN-93 were from Cayman (Ann
Arbor, MI, USA). All other chemicals were from Sigma-Aldrich
(St. Louis, MO, USA).
Mice
The generation of mice deficient in the EP1, EP2, EP3, and EP4
receptors and mPGES1 has been previously reported [10–14]. All
mice used were at least 8 wks old and were bred and maintained in
specific pathogen-free animal facilities at the University of North
Carolina (Chapel Hill, NC). Mice were killed by exposure to CO2
follow by physical euthanasia prior to collection of cells. All
experiments were carried out in accordance with the recommen-
dations in the Guide for the Care and Use of Laboratory Animals
of the National Institutes of Health. The protocol was approved by
the Institutional Animal Care and Use Committee guidelines of
the University of North Carolina (permit number:13–158).
Mast cell culture and cytokine depletion
Mast cells were derived from bone marrow isolated from mouse
tibia and cultured in complete medium (Iscove’s Modified
Dulbecco’s Medium supplemented with 12% fetal bovine serum
(FBS), 100 U/ml of Penicillin and Streptomycin, 4 mM L-
glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 100 mM
non-essential amino acid (all from GIBCO Life Technologies,
Grand Island, NY, USA)), 10 ng/ml of recombinant mouse IL-3
and 20 ng/ml of recombinant mouse SCF (both from Sigma-
Aldrich, St. Louis, MO, USA) for 4 weeks at 37uC in a humidified
incubator with 5% CO2 atmosphere. Medium was changed
weekly and adherent cells were removed regularly from cultures by
transfer of non-adherent cells to a new culture dish. Maturity of
non-adherent BMMC was assessed by measuring surface expres-
sion of FceRI and c-Kit. Only cultures with .95% cells positive
for both receptors and ,12 weeks in culture were used for
experiments.
For depletion, BMMC were washed twice in phosphate
buffered saline (PBS) and re-suspended in depletion medium (the
same as the culture medium but without IL-3 and SCF) at a
concentration 16106 cells per 1 ml. Cells were cultured at 37uC in
a humidified incubator with 5% CO2 atmosphere.
Cell death and apoptosis analysis
7AAD. Cells depleted of cytokines for various times were
stained for 15 min in 7-AAD (BD Bioscience, Franklin Lakes, NJ
USA), 5 ml per test (16106 cells) and analyzed using Fluorescence-
activated cell sorting (FACS) on a CyAn ADP analyzer (Beckman
Coulter, Inc., Brea, CA).
Mitochondrial membrane potential. Cells were stained
using JC-1 from a Flow cytometry mitochondrial membrane
potential detection kit (BD Biosciences, Franklin Lakes, NJ USA)
according to the manufacturer’s protocol. Green and red
fluorescence ratios were measured on CyAn ADP analyzer
(Beckman Coulter, Inc., Brea, CA).
Caspase-3 activation. Caspase activation was measured
with the APO LOGIX carboxyfluorescein (FAM) caspase
detection kit (Cell Technology, Inc., Mountain View, CA, USA)
specific for caspase-3 (FAM500-2) according to the manufacturer’s
protocol. Fluorescence was measured on a CyAn ADP analyzer
(Beckman Coulter, Inc., Brea, CA) and results were verified by
western blot using an antibody specific for cleaved caspase-3
antibody (#9661, Cell Signaling Technology, Danvers, MA,
USA).
Low molecular weight cleavage assessment. 36106
BMMC depleted of cytokines for 24 h were lysed in lysis buffer
(1% SDS, 0.1 M NaCl, 0.1 M EDTA, 0.05 M Tris base, 0.5 mg/
ml proteinase K, 0.1 mg/ml RNase A, pH 8) for 2 h at 55uC.
135 ml of saturated NaCl solution was added to each sample,
mixed and centrifuged for 10 min at 16,000 g. Supernatant
(400 ml) was removed, added to 800 ml 100% ethanol and
precipitated for 20 min at 220uC. Precipitated DNA was pelleted
by centrifugation at 16,000 g and washed with 0.5 ml 70%
ethanol and 0.5 ml 100% ethanol. The pellet of DNA was air
dried for 10 min at room temperature to remove trace of ethanol
and then dissolve in 30 ml TE buffer (10 mM Tris base, 1 mM
EDTA). Loading buffer was then added. Samples were separated
by electrophoreses on 1.2% agarose gel 5 V/cm for 1–2 h. The
gel was stained with ethidium bromide and visualized by trans-
illumination with UV light and photographed.
Condensed nuclei staining. BMMC depleted of cytokines
for 24 h were placed on poly-L-lysine-treated coverslips, fixed with
4% paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA) for
10 min at room temperature, and mounted on microscope slides
(Thermo Fisher Scientific Inc., Waltham, MA, USA) in 5 ml of
ProLong Gold antifade reagent with 4,6-diamidino-2-phenylin-
dole (Invitrogen, Life Technologies, Grand Island, NY, USA).
Samples were visualized using an Olympus BX61 upright
fluorescence microscope (Olympus, Center Valley, PA, USA) with
a 606 objective with a Hamamatsu ORCA RC camera
(Hamamatsu Photonics, K.K., Hamamatsu City, Japan), operated
by Velocity software (PerkinElmer Life and Analytical Sciences,
Waltham, MA, USA).
Isolation of peritoneal mast cells
Peritoneal cells from 5 congenic mice were pooled and washed
once with PBS. Cells were re-suspended in 8 ml of 70% Percoll
solution (7 ml Percoll (GE healthcare Bioscience AB, Upsala,
Sweden), 1 ml 106 concentrated PBS, 1.9 ml H2O, 0.1 ml FBS)
and overlaid with 2 ml of peritoneal mast cell medium (PMC:
DMEM, 20 mM HEPES, 5% FBS). Cells were centrifuged 650 g
at room temperature for 15 min. Supernatant was discarded and
mast cell pellets were re-suspended in 0.5 ml PMC medium,
transferred to new tubes and washed once in 10 ml pre-warmed
PMC medium.
Intracellular calcium measurement
BMMC in complete culture medium were harvested, washed
and resuspended in Hank’s balanced salt solution buffer with
Ca++, Mg++ and 0.1% BSA (HBSS, GIBCO Invitrogen) at a
concentration of 16106cells/ml. Cells were loaded with 2 mM
FURA-2/AM (Invitrogen) for 40 min, and washed twice. Changes
in dye fluorescence (excitation 340 and 380 nm, emission 510 nm)
with time after BMMC stimulation with 161026 M PGE2 were
determined by Fluostar Optima spectrometer (BMG Labtechnol-
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ogies). Calcium concentrations were calculated as described
previously [15]. For inhibition of intracellular calcium with
BAPTA was added to cell suspension 5 min before stimulation
with PGE2.
Immunoblotting analysis
Whole cell lysates in SDS-PAGE loading buffer were fractioned
by SDS-PAGE under reducing condition and electrotransferred to
PVDF membrane (Hybond-P, Amersham, GE Healthcare,
Uppsala, Sweden). The following primary antibodies were used
for immunostaining of the membranes: caspase-3 (#9661),
phospho-Erk1/2 (#9106), phospho-Akt (#5171), phospho-p38
(#9211), c-Jun (#9165), Bim (#2933) (all from Cell Signaling
Technology (Danvers, MA, USA)), b-actin (A5316, Sigma-
Aldrich, St. Louis, MO, USA). The secondary antibodies anti
mouse-HRP (#7076) anti rabbit-HRP (#7074) from Cell
Signaling Technology (Danvers, MA, USA) were utilized. All
immunostaining was done according to the manufacturer’s
protocol. Results were analyzed by a gel analysis module in the
ImageJ software (NIH, http://imagej.nih.gov/ij/index.html).
Gene expression assay
RNA was isolated with RNAbee (Tel-Test Inc., Friendswood,
TX) according to the manufacturer’s protocol and cleaned with
the Total RNA mini purification kit (Denville Scientific Inc.,
Metuchen, NJ, USA). Reverse transcription was carried out with
the High Capacity cDNA transcription kit (Applied Biosystems,
Life Technologies, Grand Island, NY, USA). Obtained cDNAs
were used for relative quantitative analysis by real-time PCR using
comparative CT method. The following primers and detection
TaqMan MGB probes were used (Bcl2l11 (Bcl-2-like protein 11/
Bim) # Mm00437796, Bbc3 (Bcl-2-binding component 3/Puma)
#Mm00519268) for cDNA amplification by ABI Prism 7 900HT
detection system in TaqMan universal PCR master mix (all from
Applied Biosystems, Life Technologies, Grand Island, NY, USA)
according to the manufacturer’s protocol. The gene expression
level was expressed as a relative expression of the gene of interest
to GAPDH expression level in each sample.
Reconstitution of mast cells in ear of Wsh/sh mice
Wsh/sh mice were lightly anesthetized and the pinna of the ears
reconstituted intradermally (i.d.) with various numbers of 5-week-
old cultured BMMC in 40 ml PBS. In other experiments mice
received intradermally to both ears 56105 BMMC, treated or not
with 161026 M PGE2 for 20 min and washed twice with PBS to
remove PGE2 before injection.
Passive cutaneous anaphylaxis
Animals were lightly anesthetized, and the pinna of the right
ears injected i.d. with 8 ng of murine monoclonal anti-DNP IgE in
20 ml of PBS. The left ears received 20 ml of PBS, i.d. Twenty-four
hours later, animals were injected i.v. with 100 ml of PBS
containing 100 mg of DNP-albumin and 1% Evan’s Blue dye.
Animals were killed 90 min after i.v. injection, and pinna of the
ears were removed close to the base and incubated in 1 ml of
formamide at 54uC for 48 h. Quantitative analysis of formamide
extracts was determined by measuring the absorbance of Evan’s
Blue at 610 nm with a spectrophotometer.
Statistical analysis
Data are represented as means 6 SEM. Statistical significance
was assessed by the Student’s two-tailed t test. When three or more
groups or variables were compered, statistical significance was
determined by ANOVA. A P value of ,0.05 was considered as
statistically significant
Results
PGE2 increases cell death during cytokine deprivation
Interleukin-3 (IL-3) and SCF are critical to mast cell survival,
both in vitro and in vivo. We took advantage of this to model cell
death of mast cells in vitro. Mast cells derived from bone marrow
of C57BL/6J mice (BMMC) in complete medium containing IL-3
and SCF, were deprived of these cytokines to initiate cell death,
either in the presence or absence of PGE2. Cell death was
evaluated as a percentage of 7-AAD-stained cells at various times
after cytokine withdrawal. Cytokine deprivation resulted in an
increase in the number of 7-AAD-stained cells, reaching 30% 24 h
and 44% 36 h after cytokine removal. Addition of 161026 M
PGE2 to the cytokine depleted medium led to a further increase in
number of 7-AAD stained cells compared to untreated BMMC
with 48% and 76% of the cells staining with the dye 24 h and 36 h
after cytokine removal, respectively. Nevertheless, addition of
161026 M PGE2 to complete medium did not result in an
increase of 7-AAD stained cells (Fig.1A). The difference in
numbers of 7-AAD-stained cells during cytokine withdrawal in
the presence or absence of PGE2 was significant (P,0.05) in
concentrations from 161026 M to 161027 M (Fig 1B). Interest-
ingly, pretreatment of mast cells with PGE2 for only 10 min in
complete medium follow by cytokine deprivation without further
addition of PGE2 to the medium was sufficient to increase the
number of 7-AAD positive cells to a similar magnitude as observed
when PGE2 was present throughout the experiment (Fig 1C). This
suggests that PGE2 can affect cell survival even after its
concentration return to homeostatic levels.
Increased cell death after PGE2 treatment is caused by
apoptosis
To further characterize the PGE2 mediated increase in BMMC
death, we measured loss of plasma membrane integrity and
extracellular translocation of phosphatidylserine (PS) with APC-
labeled Annexin V. Twenty hours after cytokine withdrawal,
about 40% of BMMC stained with Annexin V. Treatment with
PGE2 increased this number to 45% of BMMC (Fig. 2A). A
characteristic feature of cell apoptosis is a loss of mitochondrial
membrane potential (DYm), which can be measured by cationic
dye JC-1 as a potential-dependent ratio of red and green
fluorescence intensity. As shown in Fig. 2B, the decrease of red
fluorescence intensity, a sign of dissipation of DYm during cytokine
deprivation, was significantly higher in PGE2 treated BMMC
compared to un-treated BMMC. Caspase-3 is a critical execu-
tioner of apoptosis. Its activation requires proteolytic processing of
the inactive zymogen into activated p17 and p12 fragments.
Western blot analysis with antibody specific to the cleaved p17
fragment showed higher levels of this fragment in lysates prepared
from the cytokine deprived PGE2 treated BMMC compared to
similar cultures without PGE2 (Fig 2C). Consistent with this, PGE2
treatment of cytokine-deprived cells increased the number of
BMMC that stained with the fluorescently labeled inhibitor of
caspase-3 (FLICA) FAM-DEVD-FMK (Fig 2D). Similarly to
double staining with Annexin V in Fig. 2A, the majority of 7-
AAD-stained cells are also stained with FLICA (Fig. 2D),
suggesting that the increase in cell death shown in Fig 1 is directly
related to increase in caspase-3 activation and apoptosis.
Characteristic hallmarks of the late phase of apoptotic execution
are low molecular weight cleavage (LMW) of DNA and chromatin
condensation. Cytokine deprivation of both PGE2 treated and
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untreated BMMC showed a pattern of DNA fragmentation
consistent with apoptosis (Fig 2E). Similarly, the number of cells
with condensed chromatin was higher in BMMC treated with
PGE2 compare to untreated BMMCs (Fig 2F). The observation of
multiple events characteristic of apoptosis in BMMC after cytokine
withdrawal, and the increase in the magnitude of these changes in
PGE2 treated cells, is consistent with a model in which PGE2
augments the apoptotic pathway initiated by cytokine withdrawal.
PGE2 activation of the EP3 receptor increases apoptosis
BMMC express all four PGE2 receptors [16]. Therefore
BMMC were derived from mice lacking each of these receptors
and the appropriate controls. The impact of the loss of each of the
four PGE2 receptors on the ability of 1610
26 M PGE2 to
augment apoptosis initiated by cytokine withdrawal was assessed
by determining the number of 7AAD positive cells in the cultures
20 hours after initiation of the experiment. The absence of the
EP1, EP2 or EP4 receptors did not alter the augmentation of
7AAD positive cells in the PGE2 treated cultures (Fig. 3A). In
contrast, no increase in the number of 7AAD staining cells was
observed in PGE2 treated EP32/2 BMMC deprived of cytokines,
compared to untreated cultures (Fig 3A). During the experiment
we noted some variability between different clones of mast cells.
Although, mast cells generally do not produce large amounts of
Figure 1. PGE2 promotes mast cell death during cytokine deprivation. A. The percentage of 7-AAD stained mast cells after culture in
complete medium with 161026 M PGE2, in depletion medium without cytokines and in depletion medium with 1610
26M PGE2. Data are from 8
independent experiments using 2 cultures of WT BMMC. B. The percentage of 7AAD stained cells during cytokine deprivation for 16 h carried out in
the presence of various PGE2 concentrations. Data are from 8 independent experiments using 1 culture of WT BMMC. C. 7-AAD positive BMMC
pretreated with 161026 M PGE2 in complete medium for various times. Cells were depleted from cytokines for 16 h without further presence of
PGE2. Data are from 4 independent experiments using 1 culture of WT BMMC. CTRL indicates mast cells cultured in complete medium during the
experiment. ANOVA was used in B and C to evaluate statistical significance. Statistical significance: * = P,0.05, ** = P,0.01.
doi:10.1371/journal.pone.0102948.g001
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Figure 2. PGE2 increases apoptosis induced by cytokines withdrawal. A. Double staining of BMMC with 7-AAD and APC-Annexin V (upper
panel), and its quantitative analysis (lower panel). Data are from 8 independent experiments using 2 cultures of WT BMMC. B. FACS analysis of the
mitochondrial potential measured as fluorescence intensity of JC-1 staining (upper panel), and its quantitative analysis expressed as a ratio of red
PGE2 Promotes Apoptosis through EP3
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PGE2, it is possible that during cytokine deprivation and cell
death, endogenous PGE2 is released and thus PGE2 produced by
the mast cell itself augments apoptosis. This can contribute to
differences in cell death seen in various mast cell cultures. To
determine the contribution of such an autocrine loop to mast cell
apoptosis, BMMC were derived from mice lacking mPGES1
(mPGES12/2), the primary PGE2 synthase. mPGES12/2
BMMC showed a similar rate of cell death during cytokine
withdrawal and were equally sensitive to a PGE2 mediated
increase in cell death compare to wild type (WT) cells (Fig 3B).
These results show that in this model exogenous rather than
endogenous PGE2 mediates the increase in mast cell death during
cytokine withdrawal.
The absence of EP3 on BMMC eliminated PGE2 mediated
augmentation of the loss in mitochondrial membrane potential
during cytokine depletion (Fig 3C). The activity of caspase-3,
measured by presence of the cleaved p17 fragment after cytokine
depletion, was not increase by PGE2 treatment of EP32/2
BMMC, while WT, EP22/2, and EP42/2cells showed higher
levels of caspase-3 activation (Fig. 3D). Similarly, caspase-3 activity
measured by FLICA staining showed no increase in EP32/2
BMMC when treated with PGE2 (Fig.3E). Sulprostone, a
metabolism resistant synthetic analog of PGE2, is a EP3 receptor
preferring agonist. Pretreatment of mast cells with various
concentration of sulprostone in complete medium prior to
cytokine depletion resulted in concentration dependent increase
in cell death measure by 7-AAD. The similar actions of PGE2 and
sulprostone support the role of EP3 in mast cell apoptosis following
cytokine withdrawal (Fig. 3F).
Ex vivo and in vivo evaluation of mast cell survival after
exposure to PGE2
BMMCs are widely used as a model for studying mast cells in
vitro; however they are considered less mature compared to
residential mast cells. To verify our finding in primary mast cells,
peritoneal mast cells (PMC) from WT and EP3 deficient animals
were isolated on Percoll gradient with more than 98% efficiency as
describe previously [17]. PMC were cultured either in complete
medium, in cytokine-depleted medium, or in cytokine-depleted
medium with 161026 M PGE2 for 16 h. Viability was assessed by
determining the number 7AAD positive cells. As expected, a
marked increase in the number of 7-AAD staining cells was
observed in cytokine-deprived cultures. Similarly to BMMCs the
number of 7-AAD cells in the cytokine deprived cultures was
significantly increased by addition of PGE2. This action of PGE2
was dependent on the EP3 receptor as PGE2 treatment did not
increase the number of 7-AAD stained cells in PMC isolated from
EP3 deficient animals (Fig 4A). PGE2 treatment of WT PMC, but
not EP32/2 PMC also increased the number of cells staining
with caspase-3 specific FLICA compared to untreated cells
(Fig. 4B).
Study of the role of PGE2 in apoptosis in vivo is complicated by
the fact that in healthy tissue PGE2 may act to recruit circulating
mast cells progenitors and this action may also be mediated by the
EP3 receptor [18,19]. After PGE2 treatment of mice it is not
possible to distinguished cells mobilized to the site towards the
PGE2 gradient and cells already present at the site of PGE2
application. Use of sulprostone does not alleviate the problem,
since some of the pro-migratory actions of PGE2 are mediated
through the EP3 receptor. Therefore, to begin to address the in
vivo role of EP3 in apoptosis, we developed the following model.
The skin of mast cells deficient mice (Wsh/sh) is reconstituted
locally by injection of excessive numbers of BMMC, with the
anticipation that only small number of cells will survive and stably
repopulate tissue. We use the decrease in the amount of
transferred BMMC to the ear of Wsh/sh mice to evaluate the
pro-apoptotic actions of PGE2 and assess the ability of the EP3
pathway to contribute to mast cell death in vivo. EP32/2 and
wild type BMMC were briefly exposed to PGE2 washed twice with
PBS and then used to reconstitute the pinna of the ear of mast cells
deficient Wsh/sh mice. After 10 days the survival of the mast cells
was compared indirectly by examining the susceptibility of the
tissue to suboptimal passive cutaneous anaphylaxis. PCA mediated
by exogenous IgE is entirely dependent on mast cells [20].
Accordingly, the extravasation of serum proteins characteristic of
this response shows a linear relationship with the number of mast
cells introduced into tissue (Fig. 4C). Treatment of wild type but
not EP32/2 BMMC with PGE2 decreased the anaphylactic
response in the reconstituted animals (Fig. 4D). This decrease is
consistent with a decrease in survival of mast cells after activation
of the EP3 receptor in tissue lacking inflammatory cytokines.
PGE2 mediated increase in apoptosis is dependent on
intracellular calcium release and activation of MAPK
To identify the pathway(s) responsible for the PGE2 dependent
increase in apoptosis during cytokine withdrawal, we compared
activation of EP32/2 and WT mast cells, identified pathways
activated through this receptor and then evaluated the potential of
each of these pathways to contribute to mast cell apoptosis. As
we have shown, PGE2 treatment prior to cytokine removal
can augment apoptosis (Fig.1C). We used this protocol to
avoid complexities in studying PGE2 pathways after cytokine
withdrawal.
Increase in intracellular calcium mobilization after mast cell
activation by PGE2 is exclusively dependent on the expression of
the EP3 receptor [16]. To assess the role of intracellular calcium in
apoptosis, we treated BMMC with 100 mM, 50 mM, or 25 mM of
BAPTA/AM, a cell-permeating calcium chelator, for 5 min prior
to EP3 receptor activation with 161026 M PGE2. Treatment of
fluorescence (FL-2 channel) and green fluorescence (FL-1 channel). Ratios were normalized to CTRL samples in each experiment (lower panel). Data
are from 5 independent experiments using 1 culture of WT BMMC. C. Representative western blot analysis from 3 independent experiments using 1
culture of WT BMMC of caspase-3 activation measured by the presence of a cleaved p17 fragment in BMMC (upper panel), arrow indicates p17
fragment. Anti-actin antibody was used as a loading control (lower panel). D. FACS analysis of BMMC stained with 7-AAD and FLICA for caspase-3
activity (left panel), and its quantitative analysis (right panel). Data are from 5 independent experiments and 1 culture of WT BMMC. E. Agarose gel
analysis of the DNA fragmentation assay in BMMC. Mr stands for 2-Log DNA Ladder. Data are from 3 independent experiment and 1 culture of WT
BMMC. F. Chromatin condensation in BMMC stained with DAPI (upper panel), and quantitative analysis (lower panel). Figures were captured by an
Olympus BX61 upright fluorescence microscope with 406 objectives with a Hamamatsu ORCA RC camera, operated by Velocity software
(PerkinElmer Life and Analytical Sciences). Bars in insets represent 10 mm; arrows show condensed nuclei. Data are from 15 independent experiments
using 3 culture of WT BMMC. Samples: BMMC cultured in complete medium (CTRL), BMMC cultures in medium without cytokines (no cyt.), BMMC
treated with 1026 M PGE2 and cultured in medium without cytokines (no cyt. + PGE2). Student’s two-tailed t test was used to evaluate statistical
differences between cytokine deprive mast cells and cytokine deprived mast cells treated with PGE2 in B and D. Statistical significance: * = P,0.05,
** = P,0.01.
doi:10.1371/journal.pone.0102948.g002
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Figure 3. EP3 is responsible for PGE2-increased apoptosis. A. PGE2-mediated increase in mast cell death evaluated by 7-AAD staining was
determined for BMMCs lacking each of the four PGE2 receptor. Data are from 5 independent experiments using 2 cultures of each genotype. B. PGE2
mediated increase in apoptosis in mPGES12/2 BMMC. Dead cells numbers were determined by 7-AAD staining. Data are from 3 independent
experiments and 1 culture of BMMC per genotype. C. Decreased mitochondrial membrane potential in WT and EP3 2/2 BMMC measured as a
relative ratio of red and green fluorescence of JC-1 dye. Data are from 5 independent experiments using 1 culture of WT and EP3 2/2 BMMC. D.
Activity of caspase-3 in WT, EP2, EP3, and EP4 deficient BMMC identified by specific antibody to cleaved p17 caspase-3 fragment. Data are
representative of 3 experiments for EP22/2 and EP42/2 and 4 experiments for WT and EP32/2 using 1 culture of each genotype. E. Staining by
PGE2 Promotes Apoptosis through EP3
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cells with either 50 mM or 100 mM BAPTA completely inhibited
intracellular calcium release and partial inhibition of the response
was observed in 25 mM BAPTA treated cells (Fig. 5A). BMMC
were treated with this suboptimal dose of BAPTA for 5 min prior
to addition of 161026 M PGE2. After 10 minutes, cytokines,
PGE2 and BAPTA were removed and cells were cultured in
cytokine-depleted medium for 20 h. BAPTA treatment alone did
not alter the apoptosis induced by cytokine deprivation, but
completely blocked the PGE2 mediated increase in apoptosis
(Fig. 5B).
MAPK Erk 1/2 as well as p38 are activated by PGE2 [21].
PGE2 mediated activation of both MAPKs, assessed by phos-
phorylation at T202/Y204 and T180/Y182 respectively, is EP3
receptor dependent (Fig 5C and data not shown). Treatment of
cells with PD98059, an inhibitor specific for kinase of Erk1/2,
MEK1 kinase, blocked PGE2 induced T202/Y204 Erk 1/2
phosphorylation in a dose dependent manner (Fig 5D lower
panel). Erk1/2 inhibition was sufficient to completely inhibit the
increase in the number of 7-AAD stained cells in BMMC pre-
treated with PGE2 prior to cytokine deprivation (Fig. 5D upper
panel).
caspase 3 specific FLICA; example of FACS histogram (upper panel) and its quantitative analysis (lower panel). Data are from 4 independent
experiments of 1 culture of WT BMMC and EP32/2. BMMC were cultured in complete medium (CTRL or +), medium without cytokines (no cyt. or -)
and medium without cytokines in the presence 161026 M PGE2 (no cyt. + PGE2, or P) for 16 h. Student’s two-tailed t test was used to evaluate
statistical differences between cytokine deprive mast cells and cytokine deprived mast cells treated with PGE2 in A, C, and E. Statistical significance:
* = P,0.05, ** = P,0.01. F. Increase in mast cell death after 20 min treatment with various concentration of sulprostone. Cells cultured for 16 h in
complete medium (CTRL), medium without cytokines (no cyt.) and stain with 7AAD. Data from 3 independent experiments of 1 culture of WT BMMC.
doi:10.1371/journal.pone.0102948.g003
Figure 4. EP3 dependent apoptosis increase in peritoneal mast cells and in vivo. A. Peritoneal mast cells (PMC) were isolated from the
peritoneum of WT and EP3 2/2 mice and culture for 16 h in medium with (CTRL) or without (no cyt.) cytokines or with 161026 M PGE2 (no cyt +
PGE2). Cells were stained with 7-AAD. Results are from 8 independent experiments. B. Staining of PMC from WT and EP32/2 mice with FLICA specific
for caspase 3. Results are from 4 independent experiments. C. Indicated numbers of BMMC were injected to pinna of the ear of WT mice. 10 day after
injection, passive cutaneous anaphylaxis was quantified by assessing serum protein extravasation into tissue in Evans blue treated animals. n = 3
animals for each group. D. 56105 BMMC of the indicated genotypes were treated with 161026 PGE2 or vehicle for 20 min, washed 26with PBS and
injected to pinna of the ears of mast cells deficient mice (Wsh/sh). 10 day after injection, passive cutaneous anaphylaxis was assessed as in C. n = 4
animals for each group. Student’s two-tailed t test was used to evaluate statistical differences between cytokine deprive mast cells and cytokine
deprived mast cells treated with PGE2 in A and B. Statistical significance of differences in C and D were evaluated using ANOVA. Statistical
significance: * = P,0.05, ** = P,0.01.
doi:10.1371/journal.pone.0102948.g004
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Figure 5. PGE2-driven increase in apoptosis is dependent on intracellular calcium release and activation of MAPK. A. Intracellular
calcium release after stimulation with 161026 M PGE2 in untreated BMMC or in BMMC treated with various concentrations of BAPTA. Data is
representative of 3 independent experiments of 1 WT BMMC culture. B. Ability of BAPTA to inhibit PGE2 mediated augmentation of cell apoptosis
after cytokine withdrawal. Cell were treated as indicated with 25 mM BAPTA for 5 min follow by 161026 M treatment with PGE2 for 20 min. Cell death
was assessed at 16 h of depletion by staining with 7AAD. Data are from 5 independent experiments using 1 culture of WT BMMC. C. Time course of
Erk1/2 phosphorylation in WT and EP32/2 BMMC stimulated with 161026 M PGE2, representative of 3 independent experiments is shown. D.
Pharmacological inhibition of PGE2-triggered Erk1/2 phosphorylation (lower panel) and increase in apoptosis (upper panel). BMMC were activated by
161026 M PGE2. For inhibition, cells were pretreated with various concentrations of PD98059 for 10 min before PGE2 activation, n = 5 independent
experiment of 2 culture of BMMC. E. Time course of Akt phosphorylation in WT and EP32/2 BMMC stimulated with 161026 M PGE2, n = 3
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Activation of mast cells with 161026 M PGE2 resulted in rapid
Akt activation, measured by an increase in phosphoryplation at
S473 (Fig. 5E upper panels). In EP32/2 BMMC, PGE2 induced
phosphorylation of S473 was completely abolished (Fig. 5E lower
panels). Treatment of WT mast cells with LY294002, an inhibitor
of PI3 kinase responsible for activation of Akt, at concentration
higher than 10 mM resulted in complete inhibition of PGE2
induced S473 phosphorylation. However, inhibition of Akt
activation by LY294002 did not alter the ability of PGE2 to
augment BMMC apoptosis (Fig. 5F).
PGE2-stimulated MAPK activation and increase in
apoptosis upon cytokine withdrawal is Calmodulin
kinase II dependent
MAPK activation can be both calcium dependent and calcium
independent. To determine the relationship between intracellular
calcium mobilization and MAPK phosphorylation triggered by
EP3 receptor, we treated BMMC with the intracellular calcium
inhibitor BAPTA before addition of 161026 M PGE2. Inhibition
of intracellular calcium resulted in a complete inhibition of PGE2
induced Erk1/2 and p38 phosphorylation at BAPTA concentra-
tions greater than 25 mM (Fig. 6A, data not shown). Erk 1/2 could
be activated by intracellular calcium through several pathways
including calcineurin and calmodulin dependent kinase II
(CamKII) [22–24]. However, we found that activity of calcineurin
in WT and EP3 2/2 cells significantly decreased after PGE2
stimulation. Moreover a specific inhibitor of calcineurin, Cyclo-
sporine A, was not able to inhibit Erk1/2 activation (data not
shown).
To investigate a possible role of CamKII in the activation of
MAPK in BMMC by PGE2, an inhibitor with specificity for
CamKII, KN-93, was used. As shown in Fig. 6B, KN-93
effectively inhibited the PGE2 mediated increase in apoptosis
during cytokine withdrawal in a concentration dependent manner
ranging from 125 to 500 mM. At higher concentrations this agent
was toxic to BMMC. The inhibition of CamKII with KN-93
correlated with inhibition of Erk 1/2 (Fig. 6C).
PGE2 increases expression of Bim
Our results suggested that PGE2 augmented apoptosis in mast
cells through a signaling pathway that involves intracellular
calcium release and Erk 1/2 phosphorylation. As shown in Fig.2
B, an increase in apoptosis is apparent at the mitochondrial level,
suggesting that activated Erk 1/2, or events downstream of Erk 1/
2 are able to upregulate intrinsic apoptotic pathway prior to
MOMP. Bcl-2 family members Bim and Puma have been
implicated in previous studies examining mast cells apoptosis
induced by cytokine withdrawal [8]. Additionally, Erk1/2 was
shown to regulate expression of c-Jun, an established positive
regulator of Bim expression [25–27]. We therefore asked whether
the activation of the Erk1/2 pathway by PGE2 was paralleled by
alteration in the expression of genes known in these pathways.
Expression of Bim and Puma in BMMC treated with either vehicle
or PGE2 was assessed by qPCR 10 h after cytokine withdrawal. As
expected, removal of cytokines from the culture medium led to an
increase in expression of both Bim and Puma (genes Bcl2l11and
Bcc3) compared to cells growing in complete medium (Fig. 7A).
Pretreatment of BMMC with PGE2 for 20 min prior to cytokine
withdrawal significantly increase Bim expression. In contrast, no
difference between PGE2 and vehicle treated cultures was
observed in the expression of Puma. Withdrawal of cytokines
increased Bim expression also in EP32/2 cells; however, these
cells were resistant to a further increase in Bim expression after
PGE2 treatment (Fig. 7B). Inhibition of the Erk 1/2 pathway with
PD98059 prior to PGE2 treatment, also prevent the increase in
Bim expression (Fig. 7B). Previous studies have shown that PGE2
can induce apoptosis of lymphocytes, and that this response is
dependent on c-Myc although it is Bcl-2 independent [28]. RNA
from mast cells cultured in complete medium, mast cells depleted
from cytokines for 10 h, and mast cells pretreated by 1026 M
PGE2 before 10 h depletion was analyzed for both c-Myc and Bcl-
2 expression. Expression of both genes was significantly decreased
in RNA samples prepared from cells after removal of cytokines.
The presence of PGE2 did not prevent the decrease in either c-
Myc or BCL-2 (data not showed). Therefore, PGE2 increase
apoptosis induced by cytokine withdrawal is likely c-Myc and Bcl-
2 independent.
To further delineate mechanism of Bim regulation, we
evaluated changes in the protein levels of the various Bim isoforms
and assessed cells for the appearance of c-Jun after PGE2
stimulation. c-Jun levels increased rapidly in mast cells in response
to PGE2, with maximal level seen by 2 h (Fig. 7C). An increase
was also seen after 2 h of cytokine withdrawal and the increase was
greater in mast cells exposed to PGE2 (Fig. 7D, left). This
augmented production of c-Jun was EP3 dependent as no
observed increase in c-Jun was observed in lysates from
EP32/2 cells after EP3 stimulation (Fig 7D, right panel). In the
presence of cytokines only 2 isoform of Bim were identified in
BMMC lysates (Bim EL and Bim L) (Fig. 7C). 5 min stimulation
with 161026 M PGE2 lead to dramatic change in mobility of Bim
EL and BimL isoforms on western blot as both Bim isoforms
showed multiple bands probably due to their phosphorylation
(Fig. 7C). However, total Bim protein level did not significantly
changed within 6 h of PGE2 activation (Fig. 7C). In the absence of
cytokines, Bim protein level increased within 2 h of depletion and
also low expression of BimS was apparent on long exposure of films
(Fig. 7D,E). The presence of PGE2 resulted in a dramatic increase
in the amount of BimS isoform 2–10 h after cytokine depletion in
WT cells. 10 h after cytokine depletion, PGE2 stimulation also
slightly increased levels of other Bim isoforms (Fig. 7E). Cytokine
depletion of EP32/2BMMC also resulted in increased levels of
Bim, however, no further increase in expression of Bim was
observed in cells exposed to PGE2 (Fig 7D,E). Together this
suggest that cytokine withdrawal and EP3 activation work together
to modulate the levels of Bim and to alter the ratios of the various
Bim isoforms present in the mast cells.
Discussion
In this manuscript we analyzed the role of PGE2 in mast cell
apoptosis during cytokine withdrawal. In our initial observation we
found that exposure to PGE2 increases mast cell death during
cytokine deprivation. However, PGE2 was not able to induce cell
death in the presence of anti-apoptotic stimuli (grow factors and
cytokines). This suggests that PGE2 is not an inducer of cell death,
but rather it activates signaling pathway(s) which act in synergy
independent experiment of 1 culture. F. Pharmacological inhibition of Akt phosphorylation triggered by PGE2 (lower panel) and increase in apoptosis
(upper panel), BMMC were activated by 161026 M PGE2. For inhibition, cells were pretreated with various concentration of LY294002 for 10 min
before PGE2 activation, n = 6 independent experiments of 2 culture of BMMC. Differences between groups in B were evaluated by Student’s two-way
t-test, for D and F ANOVA test was used. Statistical significance: * = P,0.05, ** = P,0.01, *** = P,0.001.
doi:10.1371/journal.pone.0102948.g005
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with pro-apoptotic pathways triggered by withdrawal of cytokine.
Analysis of the mitochondrial membrane potential, caspase-3 and
late phases of apoptosis indicated that the higher number of dead
cells in cultures treated with PGE2 during cytokine deprivation is
caused by an increase in apoptosis. This further supports the
synergy of PGE2-triggered and apoptotic pathways. Moreover, the
up-regulation of all apoptotic events we analyzed suggested that
the PGE2-triggered signaling pathway modulates apoptotic events
before or during MOMP. Interestingly, pretreatment of BMMC
with PGE2 shortly before cytokine deprivation, and subsequent
absence of PGE2 during deprivation, was efficient in potentiation
of apoptosis. This raises the possibility that pathways triggered by
PGE2, or products of this pathway remained activated for a
relatively long period of time. A possible explanation for these
phenomenons is the induction of transcription of pro-apoptotic
factors from Bcl-2 family by PGE2 which regulate MOMP. This is
consistent with our overall finding that the mechanism by which
the PGE2/EP3 pathway acts is increasing Bim transcription after
cytokine withdrawal. This is also supported by the previous
findings of others that cross-linking of FceRI and activation of
mast cells, before their depletion from cytokines induce Bim and
modulate mast cell survival [29]. In neutrophils, GM-CSF
treatment temporarily blocks apoptosis by inducing anti-apoptotic
factors with rapid turnover and pro-apoptotic factors including
Bim, which limit GM-CSF-mediated prolonged survival of
neutrophils [30]. Binding sites for several transcription factors
including Foxo, c-myb, and c-jun are present in the Bim promoter
[31,32]. While c-myb and c-jun can be activated by MAPK, Foxo
expression is negatively regulated by Akt phosphorylation. It is
interesting to speculate that upregulation of Foxo during cytokine
withdrawal cooperates with induction of c-jun and/or c-myb to
facilitate increased Bim transcription. Increased expression of c-
jun and c-myb may be in part secondary to Erk activation by
PGE2 (Fig.8). Bim undergoes alternative splicing to produce three
splicing variants (BimEL, BimL and BimS). The smallest variant
BimS is the most potent inducer of apoptosis [33]. Interestingly,
BimS isoform was upregualated by EP3 dependent PGE2
activation as well as by cytokine withdrawal. PGE2 through EP3
Figure 6. PGE2-stimulated MAPK activation is dependent on calcium and calmodulin dependent kinase II. A. Erk1/2 phosphorylation is
inhibited by BAPTA. Cells were pretreated with various concentration of calcium inhibitor BAPTA before activation with 161026 M PGE2, n = 3
independent experimetns of 1 culture of BMMC. B. Calmodulin dependent kinase II specific inhibitor KN-93 inhibited PGE2 increased apoptosis.
BMMC were pretreated with various concentration of KN-93 for 10 min followed by activation with by 161026 M PGE2. Dead cells stained with 7-
AAD, n = 6 independent experiments of 3 cultures of BMMC. C. KN-93 at various concentrations inhibited Erk1/2 phosphorylation induced by
161026 M PGE2, n = 4 independent experiments of 1 cultures of BMMC. BMMC cultured in complete medium (CTRL), medium without cytokines (no
cyt.) and medium without cytokines in the presence 161026 M PGE2 (no cyt. + PGE2). Statistical significance using ANOVA: * = P,0.05, ** = P,0.01,
*** = P,0.001.
doi:10.1371/journal.pone.0102948.g006
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Figure 7. PGE2 increase Bim expression during cytokine deprivation. A. RNA was isolated from BMMC cultured in complete medium (CTRL),
medium without cytokines (no cyt.) and medium without cytokines in the presence 161026 M PGE2 (no cyt. + PGE2) for 10 h. Expression of Bim
(Bcl2l11) and Puma (Bbc3), relative to GAPDH, was assessed by real time PCR using gene specific TaqMan Gene Expression Assay. B. RNA isolated as in
A., Bim expression in WT, EP32/2, and WT cells treated with ERK 1/2 inhibitor PD98059 in presence or absence of 161026 M PGE2 during cytokine
deprivation. C. Expression of Bim isoform and c-Jun in WT BMMC in complete medium after stimulation with 161026 M PGE2 for indicated times.
Representative of 3 independent experiments is shown. D. Expression of Bim isoforms and c-Jun various times after cytokine depletion in BMMC
treated or untreated with 161026 PGE2. 1 of 6 independent experiments is shown. E. Quantitative analysis of impact of cytokine withdrawal with or
without PGE2 treatment on relative protein expression of c-Jun, BimS and total Bim in BMMC treated with 1610
26 M PGE2 during cytokines
withdrawal. Data are from panels shown in C and D sections of this figure as well as from additional experiments (not shown). AU-arbitrary units, n = 6
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receptor cause changes in mobility of BimL and BimEL proteins
due to phosphorylation, which alter Bim binding capacity with
anti-apoptotic members of Bcl-2 family as well as its degradation.
Balance between degradation of phosphorylated BimEL and BimL
isoforms and up regulated expression of all 3 isoforms by
transcription factors is dramatically shifted during cytokine
withdrawal of PGE2 treated BMMC toward increased expression
and apoptosis.
Sustained intracellular calcium release has been reported as a
pro-apoptotic stimulus in many cells [34]. An increase in
intracellular calcium is also a distinguishing event during mast
cell activation by PGE2 [16,21]. Indeed, we found that calcium is
required for both PGE2-triggered up-regulation of apoptosis and
Erk1/2 activation in mast cells (Fig. 4 and 5). Interestingly, partial
inhibition of intracellular calcium release (25 mM BAPTA) was
sufficient to inhibit both upregulated apoptosis and Erk 1/2
phosphorylation (Fig. 4 and 5), suggesting a need for strong
intracellular calcium activation. Although this data implies that
intracellular calcium acts on apoptosis through activation of Erk
1/2, we cannot exclude the possibility that part of the increased
apoptosis after PGE2 treatment is caused directly by intracellular
calcium release. However, MEK inhibition of the PGE2-depen-
dent increase in Bim expression makes this unlikely. Our data
support a model in which EP3/calcium/CamKII/Erk/Bim
signaling is the PGE2-triggered pathway responsible for increased
apoptosis (Fig 8).
The role of Erk1/2 in cell survival is well characterized;
however, recent evidence suggests that the activation of Erk1/2
also contributes to cell death. Erk 1/2 activation was shown to
contribute to apoptosis by cisplatin [35], heavy ion irradiation
therapy using a carbon beam [36], exposure to reactive oxygen
species [37] or deprivation of pro-survival factors [38]. Erk1/2 can
potentiate apoptosis by upregulation of caspase-3 activation,
induction of p53 and other pro-apoptotic factor, expression of
death ligands, and suppression of pro-survival activity of Akt (for
review see [39]). Although these studies support the pro-apoptotic
nature of Erk1/2 phosphorylation, the basis for Erk1/2 signaling
in those events is not clear. It has been reported that prolonged
Erk1/2 activation leads to a pro-apoptotic effect of Erk1/2 while
transient activation protects against apoptosis. This is consistent
with recent results obtained from mast cells deficient in SHP1
phosphatase, which is responsible for dephosphorylation of Erk1/2
[40]. Stimulation of cells with a low concentration of IL-3 protects
against apoptosis in SHP1 negative cells, while a higher
independent experiments of 2 culture of WT and EP32/2 BMMC. Student’s two-tailed t test was used to evaluate statistical differences between
cytokine deprive mast cells and cytokine deprived mast cells treated with PGE2 in A nad B. Statistical significance: * = P,0.05.
doi:10.1371/journal.pone.0102948.g007
Figure 8. Schematic depicting of EP3 induced signaling pathway contribution to apoptosis during cytokine withdrawal. Withdrawal
of cytokines results in activation of intrinsic apoptotic pathway due to imbalance between Bcl-2 anti-apoptotic protein family members and BH3 only
pro-apoptotic proteins. Intrinsic apoptotic pathway in mast cells is upregulated by PGE2 via EP3 receptor and Ca
2+-CaMII-ERK1/2 pathway. While Erk
1/2 mediated phosphorylation of BimEL and Bim L immediately after PGE2 stimulation and this leads to ubiquination and degradation of these
isoforms, Erk also induces expression of c-Jun, a potent upregulator of Bim expression. Final outcome of Erk regulation of Bim is a balance between
Bim degradation after its phosphorylation and increase in its expression due to c-Jun. Data presented here support view that increase expression of
Bim and proapoptotic action of EP3-Ca2+-CamKII –Erk1/2 pathway is prevalent in mast cells in presence of PGE2 and during cytokine withdrawal.
doi:10.1371/journal.pone.0102948.g008
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concentration of IL-3 promotes apoptosis and shows strong
prolonged activation of Erk1/2. This suggests that the kinetics
and duration of Erk1/2 activation might determine the effect of
Erk1/2 on cell fate. Strong phosphorylation of Erk1/2, found after
activation of mast cells with PGE2 supports this view.
Several previous reports have described the ability of PGE2 to
either potentiate cell death [28,41,42] or protect against it [43,44].
The contradictory outcomes reported likely reflect that the impact
of PGE2 on cell death depends on cell types and death stimuli.
Stimulation of EP2 and EP4 is mostly reported as anti-apoptotic,
while stimulation of EP3 and EP1 are reported as pro-apoptotic or
without an effect. It is likely that the relative expression of each EP
receptor determines the final outcome of PGE2. For example,
neutrophils express relatively more EP2 and EP4 receptors
compared to EP3, while in BMMC, EP3 is the predominant EP
receptor. Treatment of neutrophils with PGE2 protects them from
apoptosis [45,46], however treatment of BMMC and peritoneal
mast cells by PGE2 as we report here up-regulates apoptosis.
Similarly to mast cells, studies from other cells have found that the
EP3 receptor augments apoptosis. In human neutrophils, a
selective agonist of EP3, ONO-AE-248, induces death by
disruption of mitochondrial potential without chromatin conden-
sation, DNA fragmentation, or expression of PS on the plasma
membrane [47]. EP3 was shown to mediate neurotoxicity on
exposure to PGE2 during ischemia, or ischemic stroke through
enhancement of inflammatory and apoptotic reactions in the
ischemic cortex [41]. In colon carcinogenesis, EP3 plays an
important role in suppression of cell growth and its down
regulation enhances the late stages of this disease [48].
In summary, even brief and transient exposure to physiologi-
cally relevant levels of PGE2 can increase mast cell apoptosis
during cytokine deprivation. We provide evidence that PGE2
mediates this action solely through the EP3 receptor. This increase
in mast cell apoptosis is dependent on synergy between the EP3/
calcium/CamKII/Erk pathway and intrinsic apoptotic pathways.
Our analysis suggests that this pathway increases Bim expression
and also may alter the relative levels of the various Bim isoforms,
in particular the pro-apoptotic BimS isoform. The unique ability of
PGE2 to increase apoptosis in mast cells could play an important
role during resolution of allergic inflammation and suggest that
while Nonsteroidal anti-inflammatory drugs (NSAID) can limit
many symptoms of inflammation they also may prolong recovery
in some instances.
Acknowledgments
The authors thank Anne Latour for technical assistance, and Peter W.
Repenning, and Rebecca Day for assistance in breeding lines and
genotyping mice.
Author Contributions
Conceived and designed the experiments: MK BHK. Performed the
experiments: MK. Analyzed the data: MK BHK. Contributed reagents/
materials/analysis tools: MK BHK. Contributed to the writing of the
manuscript: MK BHK.
References
1. Kovarova M, Rivera J (2004) A molecular understanding of mast cell activation
and the promise of anti-allergic therapeutics. Curr Med Chem 11: 2083–2091.
2. Gibson PG, Allen CJ, Yang JP, Wong BJ, Dolovich J, et al. (1993) Intraepithelial
mast cells in allergic and nonallergic asthma. Assessment using bronchial
brushings. Am Rev Respir Dis 148: 80–86.
3. Brightling CE, Bradding P, Symon FA, Holgate ST, Wardlaw AJ, et al. (2002)
Mast-cell infiltration of airway smooth muscle in asthma. N Engl J Med 346:
1699–1705.
4. Viegas M, Gomez E, Brooks J, Davies RJ (1987) Changes in nasal mast cell
numbers in and out of the pollen season. Int Arch Allergy Appl Immunol 82:
275–276.
5. Godfrey HP, Ilardi C, Engber W, Graziano FM (1984) Quantitation of human
synovial mast cells in rheumatoid arthritis and other rheumatic diseases. Arthritis
Rheum 27: 852–856.
6. Hershko AY, Charles N, Olivera A, Alvarez-Errico D, Rivera J Cutting edge:
persistence of increased mast cell numbers in tissues links dermatitis to enhanced
airway disease in a mouse model of atopy. J Immunol 188: 531–535.
7. Galluzzi L, Vitale I, Abrams JM, Alnemri ES, Baehrecke EH, et al. (2012)
Molecular definitions of cell death subroutines: recommendations of the
Nomenclature Committee on Cell Death 2012. Cell Death Differ 19: 107–120.
8. Ekoff M, Nilsson G (2011) Mast cell apoptosis and survival. Adv Exp Med Biol
716: 47–60.
9. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN (2001) Lipid mediator
class switching during acute inflammation: signals in resolution. Nat Immunol 2:
612–619.
10. Stock JL, Shinjo K, Burkhardt J, Roach M, Taniguchi K, et al. (2001) The
prostaglandin E2 EP1 receptor mediates pain perception and regulates blood
pressure. J Clin Invest 107: 325–331.
11. Tilley SL, Audoly LP, Hicks EH, Kim HS, Flannery PJ, et al. (1999)
Reproductive failure and reduced blood pressure in mice lacking the EP2
prostaglandin E2 receptor. J Clin Invest 103: 1539–1545.
12. Nguyen M, Camenisch T, Snouwaert JN, Hicks E, Coffman TM, et al. (1997)
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular
system at birth. Nature 390: 78–81.
13. Fleming EF, Athirakul K, Oliverio MI, Key M, Goulet J, et al. (1998) Urinary
concentrating function in mice lacking EP3 receptors for prostaglandin E2.
Am J Physiol 275: F955–961.
14. Trebino CE, Stock JL, Gibbons CP, Naiman BM, Wachtmann TS, et al. (2003)
Impaired inflammatory and pain responses in mice lacking an inducible
prostaglandin E synthase. Proc Natl Acad Sci U S A 100: 9044–9049.
15. Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+
indicators with greatly improved fluorescence properties. J Biol Chem 260:
3440–3450.
16. Nguyen M, Pace AJ, Koller BH (2005) Age-induced reprogramming of mast cell
degranulation. J Immunol 175: 5701–5707.
17. Kovarova M (2013) Isolation and characterization of mast cells in mouse models
of allergic diseases. Methods Mol Biol 1032: 109–119.
18. Halova I, Draberova L, Draber P (2012) Mast cell chemotaxis - chemoat-
tractants and signaling pathways. Front Immunol 3: 119.
19. Weller CL, Collington SJ, Hartnell A, Conroy DM, Kaise T, et al. (2007)
Chemotactic action of prostaglandin E2 on mouse mast cells acting via the
PGE2 receptor 3. Proc Natl Acad Sci U S A 104: 11712–11717.
20. Finkelman FD (2007) Anaphylaxis: lessons from mouse models. J Allergy Clin
Immunol 120: 506–515; quiz 516–507.
21. Kuehn HS, Beaven MA, Ma HT, Kim MS, Metcalfe DD, et al. (2008)
Synergistic activation of phospholipases Cgamma and Cbeta: a novel
mechanism for PI3K-independent enhancement of FcepsilonRI-induced mast
cell mediator release. Cell Signal 20: 625–636.
22. Dougherty MK, Ritt DA, Zhou M, Specht SI, Monson DM, et al. (2009) KSR2
is a calcineurin substrate that promotes ERK cascade activation in response to
calcium signals. Mol Cell 34: 652–662.
23. Liu J, Zhou R, He Q, Li WI, Zhang T, et al. (2009) Calmodulin kinase II
activation of mitogen-activated protein kinase in PC12 cell following all-trans
retinoic acid treatment. Neurotoxicology 30: 599–604.
24. Illario M, Cavallo AL, Bayer KU, Di Matola T, Fenzi G, et al. (2003) Calcium/
calmodulin-dependent protein kinase II binds to Raf-1 and modulates integrin-
stimulated ERK activation. J Biol Chem 278: 45101–45108.
25. Whitfield J, Neame SJ, Paquet L, Bernard O, Ham J (2001) Dominant-negative
c-Jun promotes neuronal survival by reducing BIM expression and inhibiting
mitochondrial cytochrome c release. Neuron 29: 629–643.
26. Kayahara M, Wang X, Tournier C (2005) Selective regulation of c-jun gene
expression by mitogen-activated protein kinases via the 12-o-tetradecanoyl-
phorbol-13-acetate- responsive element and myocyte enhancer factor 2 binding
sites. Mol Cell Biol 25: 3784–3792.
27. Leppa S, Saffrich R, Ansorge W, Bohmann D (1998) Differential regulation of c-
Jun by ERK and JNK during PC12 cell differentiation. EMBO J 17: 4404–4413.
28. Pica F, Franzese O, D’Onofrio C, Bonmassar E, Favalli C, et al. (1996)
Prostaglandin E2 induces apoptosis in resting immature and mature human
lymphocytes: a c-Myc-dependent and Bcl-2-independent associated pathway.
J Pharmacol Exp Ther 277: 1793–1800.
29. Alfredsson J, Puthalakath H, Martin H, Strasser A, Nilsson G (2005)
Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell
survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell
Death Differ 12: 136–144.
30. Andina N, Conus S, Schneider EM, Fey MF, Simon HU (2009) Induction of
Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death
Differ 16: 1248–1255.
31. Biswas SC, Shi Y, Sproul A, Greene LA (2007) Pro-apoptotic Bim induction in
response to nerve growth factor deprivation requires simultaneous activation of
three different death signaling pathways. J Biol Chem 282: 29368–29374.
PGE2 Promotes Apoptosis through EP3
PLOS ONE | www.plosone.org 14 July 2014 | Volume 9 | Issue 7 | e102948
32. Bouillet P, Zhang LC, Huang DC, Webb GC, Bottema CD, et al. (2001) Gene
structure alternative splicing, and chromosomal localization of pro-apoptotic
Bcl-2 relative Bim. Mamm Genome 12: 163–168.
33. Hara H, Takeda T, Yamamoto N, Furuya K, Hirose K, et al. (2013) Zinc-
induced modulation of SRSF6 activity alters Bim splicing to promote generation
of the most potent apoptotic isoform BimS. FEBS J 280: 3313–3327.
34. Orrenius S, Zhivotovsky B, Nicotera P (2003) Regulation of cell death: the
calcium-apoptosis link. Nat Rev Mol Cell Biol 4: 552–565.
35. Nowak G (2002) Protein kinase C-alpha and ERK1/2 mediate mitochondrial
dysfunction, decreases in active Na+ transport, and cisplatin-induced apoptosis
in renal cells. J Biol Chem 277: 43377–43388.
36. Tomiyama A, Tachibana K, Suzuki K, Seino S, Sunayama J, et al. (2010)
MEK-ERK-dependent multiple caspase activation by mitochondrial proapop-
totic Bcl-2 family proteins is essential for heavy ion irradiation-induced glioma
cell death. Cell Death and Dis 1: e60.
37. Ramachandiran S, Huang Q, Dong J, Lau SS, Monks TJ (2002) Mitogen-
Activated Protein Kinases Contribute to Reactive Oxygen Species-Induced Cell
Death in Renal Proximal Tubule Epithelial Cells. Chemical Research in
Toxicology 15: 1635–1642.
38. Sinha D, Bannergee S, Schwartz JH, Lieberthal W, Levine JS (2004) Inhibition
of Ligand-independent ERK1/2 Activity in Kidney Proximal Tubular Cells
Deprived of Soluble Survival Factors Up-regulates Akt and Prevents Apoptosis.
Journal of Biological Chemistry 279: 10962–10972.
39. Zhuang S, Schnellmann RG (2006) A Death-Promoting Role for Extracellular
Signal-Regulated Kinase. Journal of Pharmacology and Experimental Thera-
peutics 319: 991–997.
40. Nakata K, Suzuki Y, Inoue T, Ra C, Yakura H, et al. (2011) Deficiency of SHP1
leads to sustained and increased ERK activation in mast cells, thereby inhibiting
IL-3-dependent proliferation and cell death. Mol Immunol 48: 472–480.
41. Ikeda-Matsuo Y, Tanji H, Narumiya S, Sasaki Y (2011) Inhibition of
prostaglandin E2 EP3 receptors improves stroke injury via anti-inflammatory
and anti-apoptotic mechanisms. J Neuroimmunol 238: 34–43.
42. Huang SK, White ES, Wettlaufer SH, Grifka H, Hogaboam CM, et al. (2009)
Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival
pathways. FASEB J 23: 4317–4326.
43. Leone V, di Palma A, Ricchi P, Acquaviva F, Giannouli M, et al. (2007) PGE2
inhibits apoptosis in human adenocarcinoma Caco-2 cell line through Ras-PI3K
association and cAMP-dependent kinase A activation. Am J Physiol Gastrointest
Liver Physiol 293: G673–681.
44. Porter BO, Malek TR (1999) Prostaglandin E2 inhibits T cell activation-induced
apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand
induction. Eur J Immunol 29: 2360–2365.
45. Rossi AG, Cousin JM, Dransfield I, Lawson MF, Chilvers ER, et al. (1995)
Agents that elevate cAMP inhibit human neutrophil apoptosis. Biochem Biophys
Res Commun 217: 892–899.
46. Ottonello L, Gonella R, Dapino P, Sacchetti C, Dallegri F (1998) Prostaglandin
E2 inhibits apoptosis in human neutrophilic polymorphonuclear leukocytes: role
of intracellular cyclic AMP levels. Exp Hematol 26: 895–902.
47. Liu J, Akahoshi T, Jiang S, Namai R, Kitasato H, et al. (2000) Induction of
neutrophil death resembling neither apoptosis nor necrosis by ONO-AE-248, a
selective agonist for PGE2 receptor subtype 3. J Leukoc Biol 68: 187–193.
48. Shoji Y, Takahashi M, Kitamura T, Watanabe K, Kawamori T, et al. (2004)
Downregulation of prostaglandin E receptor subtype EP3 during colon cancer
development. Gut 53: 1151–1158.
PGE2 Promotes Apoptosis through EP3
PLOS ONE | www.plosone.org 15 July 2014 | Volume 9 | Issue 7 | e102948
